1 it in order to understand any ART use in the
interim.
2 and proxy indicators need to be used in the
interim.
3 ia in Solid Tumors (PERCIST) versus those of
interim (
18)F fluorothymidine (FLT) PET/CT and simple vi
4 Early (or
interim) (
18)F-fluorodeoxyglucose positron emission tomo
5 At this
interim 3-year time point, comorbidities were significan
6 The
interim (
after cycle 2) FDG and FLT PET/CT studies were
7 ined by investigator review at the first two
interim analyses (HR, 0.49; 95% CI, 0.41 to 0.60; P < .0
8 We report the results of long-term follow-up
interim analyses and integrated efficacy analyses.
9 We did two
interim analyses and stopped the trial after the second
10 Here, we present the preplanned
interim analyses at 6 months of a tetravalent dengue vac
11 Interim analyses crossed the futility boundaries for dem
12 Interim analyses of a phase 1b clinical trial have sugge
13 PRETATION: Substantiating the results of the
interim analyses of KEYNOTE-006, pembrolizumab continued
14 Interim analyses of overall survival showed 9-month surv
15 castration-resistant prostate cancer at the
interim analyses of the COU-AA-302 trial.
16 Interim analyses of the phase 3 KEYNOTE-006 study showed
17 increased cardiovascular risk, based on the
interim analyses performed after 25% and 50% of planned
18 Interim analyses relying on short follow-up and includin
19 Preplanned
interim analyses were assessed per protocol and were agr
20 Treatment duration was event-driven, and
interim analyses were planned and conducted after approx
21 Two
interim analyses were planned.
22 Interim analyses were prespecified at 5 years of follow-
23 omised controlled trial (SRCT) with up to 20
interim analyses, and, as a reference case, a convention
24 After three
interim analyses, the study was unblinded at a median fo
25 al randomised controlled trial (RCT) without
interim analyses.
26 0.4) in the bortezomib group at a preplanned
interim analysis (hazard ratio [HR] 0.53 [95% CI 0.44-0.
27 roved overall survival (OS) after the second
interim analysis (in 2012) of 271 deaths in the Gynecolo
28 e primary endpoint was met at the preplanned
interim analysis (March 10, 2015).
29 At the first preplanned
interim analysis (March, 2016), the independent data mon
30 Arm C was closed for futility at the first
interim analysis (n = 241), and arm A (n = 267) and arm
31 Results of the preplanned
interim analysis (n=15 in each group) of the primary end
32 At the pre-planned
interim analysis (Oct 14, 2013), the IDMC selected trast
33 An
interim analysis (performed after 15 subjects completed
34 We did a planned
interim analysis after 219 (41%) deaths had occurred to
35 free survival at day 56 was met at a planned
interim analysis after 235 patients (of 372) were enroll
36 The trial was stopped upon predefined
interim analysis after 30 patients because of significan
37 ter 378 expected events, with a confidential
interim analysis after approximately 87 events (25% inte
38 Interim analysis after inclusion of 53 patients (50%) wi
39 The study was terminated at the
interim analysis after randomizing 30 patients.
40 We report the results of a prespecified
interim analysis after two-thirds of the planned study e
41 g committee reviewed the data at the planned
interim analysis and declared overall survival superiori
42 ly improved progression-free survival at the
interim analysis and had a favorable risk-benefit profil
43 due to futility for efficacy at an unplanned
interim analysis and increased rates of safety end point
44 trial was closed after the second scheduled
interim analysis because of slow accrual and the end of
45 f improvement did not cross the prespecified
interim analysis boundary of P=0.000019.
46 The pre-planned
interim analysis done by intention to treat was done aft
47 and July 9, 2014, and assessed through to an
interim analysis done on Jan 26, 2016.
48 Positive
interim analysis findings from four large adjuvant trial
49 The study was stopped early at the planned
interim analysis in July, 2015, because the study met it
50 The
interim analysis included 210 patients randomized to TTF
51 This
interim analysis included 90 patients who received idaru
52 The results of this
interim analysis indicate that rVSV-ZEBOV might be highl
53 An
interim analysis is scheduled after the first 30 patient
54 The study was terminated when the second
interim analysis met the prespecified futility stopping
55 nitoring board because the second preplanned
interim analysis met the prespecified stopping rule for
56 In this
interim analysis of 315 patients with glioblastoma who h
57 Anderson Cancer Center, and before a planned
interim analysis of 44 events.
58 In this
interim analysis of a multicentre, open-label, non-rando
59 We previously reported the
interim analysis of a multicentre, randomised, double-bl
60 We did this
interim analysis of a non-randomised, phase 2 trial at 2
61 wever, trial sequential analyses (similar to
interim analysis of a randomized trial) powered for a 25
62 ata monitoring committee report of a planned
interim analysis of a trial in second-line SQ NSCLC (CM0
63 We report the results of an
interim analysis of a trial of rVSV-ZEBOV in Guinea, wes
64 A planned
interim analysis of change in alanine aminotransferase a
65 l to cohort 2 was stopped after an unplanned
interim analysis of cohort 1 and the statistical analysi
66 on for cohorts 5, 6, and 7 occurred after an
interim analysis of data for cohorts 1 to 4.
67 An
interim analysis of data from the HIV Prevention Trials
68 The
interim analysis of OS (64% censored) demonstrated a 13%
69 At the second
interim analysis of overall survival (58% maturity), ove
70 We present data from the second
interim analysis of overall survival and a retrospective
71 as specified in the protocol; a prespecified
interim analysis of overall survival was conducted and i
72 In the planned
interim analysis of overall survival, 14 deaths occurred
73 We report results from a preplanned second
interim analysis of overall survival, which was planned
74 Data presented are from the planned primary
interim analysis of part one of the study when all patie
75 y for futility based on results of a planned
interim analysis of participants enrolled at least 5 yea
76 primary endpoint at the prespecified second
interim analysis of progression-free survival in the int
77 On the basis of an
interim analysis of the first 188 patients who completed
78 eath ligand 1 (PD-L1) and report here on the
interim analysis of the malignant pleural mesothelioma c
79 We report data from the
interim analysis of the ongoing VIVIANE study, the aim o
80 not enrolling participants; results for the
interim analysis of the primary endpoint are presented.
81 A planned
interim analysis of the primary outcome showed improved
82 at 1 year after the end of treatment, as an
interim analysis of the REP 301-LTF trial (planned durat
83 This trial is ongoing; here, we report an
interim analysis of the SCLC cohort.
84 This report is a prespecified, 3-year
interim analysis of the trial.
85 We report an
interim analysis of this ongoing trial.
86 This report is the third
interim analysis of this study.
87 An
interim analysis of this trial is reported here.
88 lyses and stopped the trial after the second
interim analysis on Aug 3, 2013, as directed by the data
89 comparisons, which stopped accrual early at
interim analysis on the basis of failure-free survival.
90 rior to phase 3 for treatment futility after
interim analysis on the recommendations of an independen
91 The
interim analysis presented here was protocol-specified a
92 This
interim analysis reports outcomes of 60 patients with a
93 INTERPRETATION: The results of this
interim analysis show that venetoclax has durable clinic
94 data and safety monitoring board, after the
interim analysis showed efficacy of hypothermia.
95 The study was stopped after
interim analysis showed higher mortality in the pyridoxa
96 d Kingdom had been enrolled in the trial, an
interim analysis showed increased mortality at a correct
97 A prespecified
interim analysis showed that the rate of progression-fre
98 men With Mammography-Negative Dense Breasts'
interim analysis shows that ultrasound has better increm
99 Planned
interim analysis using the O'Brien-Fleming boundary was
100 A planned
interim analysis was conducted at 69.8% of expected even
101 A preplanned
interim analysis was conducted to identify the regimen t
102 The primary endpoint of this 6 month
interim analysis was geometric mean titres (GMTs) of neu
103 The cutoff date for this prespecified
interim analysis was Jan 3, 2017.
104 A preplanned
interim analysis was performed on January 29, 2016, afte
105 Preplanned
interim analysis was performed on the first 120 patients
106 Interim analysis was performed when 221 patients died (1
107 One
interim analysis was planned to allow the study to stop
108 An
interim analysis was pre-planned after 500 patients achi
109 The primary endpoint of this
interim analysis was the proportion of patients who lost
110 This prespecified
interim analysis was to be conducted on the first 315 pa
111 The aim of this second
interim analysis was to compare overall survival between
112 This study is ongoing; data for this
interim analysis were collected per regulatory agencies'
113 Median PFS at the protocol prespecified
interim analysis with 58 PFS events (primary end point)
114 significantly improved with pertuzumab in an
interim analysis without the median being reached.
115 analysis after approximately 87 events (25%
interim analysis) to assess a noninferiority HR of 2.0 f
116 d points, including overall survival (at the
interim analysis).
117 At the time of the
interim analysis, 142 participants were evaluable.
118 en the study was stopped after a pre-planned
interim analysis, 396 patients were randomly assigned (1
119 At the time of the
interim analysis, 745 (99%) of the planned 748 patients
120 At the prespecified
interim analysis, 82 participants progressed to CNV, 51
121 In the
interim analysis, a significantly higher percentage of i
122 val, with an overall survival benefit at the
interim analysis, among patients with newly diagnosed mu
123 11 (last patient visit July, 2011), after an
interim analysis, and suggested a change in primary outc
124 The trial was stopped for futility after the
interim analysis, because the results in the experimenta
125 e unmasking took place at age 2 years for an
interim analysis, but participants and nearly all invest
126 At the
interim analysis, HRQoL was assessed with the Functional
127 For the 25%
interim analysis, MACE occurred in 59 placebo-treated pa
128 At the first scheduled
interim analysis, non-inferiority was shown and the spon
129 In this
interim analysis, patients were assessed for the occurre
130 The trial is closed and this is the first
interim analysis, reporting the objective response prima
131 On May 15, 2015, on the basis of an
interim analysis, the data and safety monitoring board d
132 At its first
interim analysis, the Data Monitoring and Ethics Committ
133 At first
interim analysis, the hazard ratio (HR) by independent r
134 At the time of the
interim analysis, the median follow-up was 29.4 months (
135 At the time of a preplanned
interim analysis, the primary efficacy analysis populati
136 At
interim analysis, the primary end point was significantl
137 At the first prespecified
interim analysis, the study was stopped early on the rec
138 utility boundary was crossed at a preplanned
interim analysis, trial accrual terminated in April, 201
139 This is an
interim analysis, up to Nov 1, 2012, when the trial was
140 Study was terminated prematurely after
interim analysis, which showed no difference in overall
141 test for paired binary data in a preplanned
interim analysis.
142 from this study based on an unplanned second
interim analysis.
143 nts and was discontinued for futility at the
interim analysis.
144 275) were closed for futility at the second
interim analysis.
145 nts after washout; after 12 weeks, we did an
interim analysis.
146 We report on a planned
interim analysis.
147 s terminated for futility after a preplanned
interim analysis.
148 ed over from placebo to pertuzumab after the
interim analysis.
149 vival was not reached in either group at the
interim analysis.
150 of 7651 people were included in the planned
interim analysis.
151 minated based on the results of this planned
interim analysis.
152 icacy thresholds were not met at the planned
interim analysis.
153 s terminated for futility after a preplanned
interim analysis.
154 nded by the safety committee after a planned
interim analysis.
155 pped the study for futility after the second
interim analysis.
156 concluded early for futility after a planned
interim analysis.
157 onsor stopped the trial after a prespecified
interim analysis.
158 ped because of the results of a prespecified
interim analysis.
159 Data reported are from the
interim analysis.
160 imary end point was tested in a prespecified
interim analysis.
161 groups for this prospectively planned second
interim analysis.
162 urrence of 2 deaths in the placebo arm in an
interim analysis.
163 than with bortezomib and dexamethasone in an
interim analysis.
164 tical comparisons were done post hoc in this
interim analysis.
165 f an overall survival benefit was seen in an
interim analysis; confirmation will be required in the p
166 Interim and end-of-treatment PET/CT have become central
167 e event information), assessed at the second
interim and final analysis by the masked Data and Safety
168 each stratum, to guide the interpretation of
interim and final analysis.
169 Using station observations, ERA-
Interim and MERRA2 reanalysis, we find that wet season p
170 a about the significance of (18)F-FDG PET at
interim assessment and end of treatment in pediatric Hod
171 The results add weight to the
interim assessment that rVSV-ZEBOV offers substantial pr
172 NTERPRETATION: The results add weight to the
interim assessment that rVSV-ZEBOV offers substantial pr
173 diagnosed with internalizing disorder in the
interim (
beta=-0.111, 95% CI: -0.184, -0.037, P=0.003).
174 protocol and compared its performance to the
interim Centers for Disease Control and Prevention-recom
175 Detectable
interim circulating tumour DNA had a positive predictive
176 Interim circulating tumour DNA is a promising biomarker
177 scuss some highly touted hypotheses and draw
interim conclusions about what is known and what could b
178 en analyzed as a time-dependent variable, an
interim CV event was associated with a higher risk of su
179 Interim CV events (heart failure, myocardial infarction,
180 was detectable in 6.3% participants without
interim CVD events by follow-up cardiac magnetic resonan
181 among 2831 participants who remained free of
interim CVD events; of these, 1723 received gadolinium-e
182 In this Article, we report
interim data (up to Jan 11, 2013) to support longer-term
183 Adaptive trial designs use
interim data analysis to amend trials, and have been rec
184 After public release of confidential
interim data by the sponsor, the academic leadership of
185 Observational analysis based on
interim data from 16 rural Kenyan (n = 6) and Ugandan (n
186 We report
interim data from a phase I/II dose-escalation/expansion
187 This paper reports Day 43 planned
interim data.
188 tors from the time of randomisation until an
interim database lock at week 16, and was open label fro
189 of 12 months; all reported results are from
interim databases.
190 egression analysis explored risk factors for
interim death or cardiac transplantation.
191 atment FDG PET/CT studies to determine which
interim examination and/or criteria best predicted the r
192 the interpretability and reproducibility of
interim FDG-PET/CT (eg, the Deauville 5-point system), a
193 Based on results of
interim FDG-PET/CT, therapy may be subsequently modified
194 lity therapy, even in patients with negative
interim FDG-PET/CT.
195 Department of Agriculture recently issued an
interim final rule governing the sale of foods and bever
196 We ascertained
interim first, second, and third heart failure hospitali
197 Conclusion Early
interim FLT PET/CT had a significantly higher PPV than s
198 o compare the performance characteristics of
interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) pos
199 II Intergroup clinical trial that used early
interim fluorodeoxyglucose positron emission tomography
200 and drinking behaviors were assessed in the
interim follow-up period.
201 patients and was terminated after a planned
interim futility analysis.
202 In the
interim,
future studies should assess conflict from the
203 denoscopy was performed after 4 wk to assess
interim gastrointestinal health.
204 ed to reduce hypoxic area to 5,000 km(2) The
interim goal of a 20% load reduction is expected to prod
205 This document should be considered as
interim guidance based on consensus among the following
206 program of PM2.5 mitigation in line with WHO
interim guidelines could avoid 750000 (23%) of the 3.2 m
207 st to the redrafting of the 2014 national UK
interim guidelines for the public health management of d
208 Interim guidelines have already been published which inc
209 clinical trials based on accumulated data at
interim has received much attention because of its flexi
210 entricular mass index, left atrial area, and
interim heart failure events partially attenuated the as
211 We sought to determine how
interim heart failure hospitalizations modify the subseq
212 3.01 (interquartile range=1.56-4.99) years,
interim heart failure hospitalizations occurred in 359 (
213 We conclude that recurrent
interim heart failure is associated with a stepwise incr
214 d every 4 or every 12 weeks with placebo for
interim infusions for 1 year.
215 iring at least quarterly dosing and allowing
interim injections based on anatomic and visual assessme
216 8)F-FLT PET was performed at baseline and at
interim (
iPET) after 1-2 cycles of therapy.
217 In the
interim,
it has been increasingly appreciated that TME a
218 goal and to determine the effect of the 20%
interim load reduction.
219 00-km(2) 5-y average hypoxic zone and set an
interim load target of a 20% reduction of the spring nit
220 -MTX) or Capizzi methotrexate (C-MTX) during
interim maintenance (IM) or prednisone or dexamethasone
221 ly assigned to high-dose methotrexate during
interim maintenance 1 versus those randomly assigned to
222 g-dose methotrexate plus pegaspargase during
interim maintenance 1.
223 hotrexate without folinic acid rescue during
interim maintenance courses.
224 in very large sample sizes, meanwhile, as an
interim measure, exome arrays allow rare non-synonymous
225 Survival analysis, logistic regression, and
interim monitoring are also discussed.
226 Interim monitoring of circulating tumour DNA at the end
227 The prespecified
interim monitoring plan was to report for futility if th
228 Planned
interim monitoring showed the superiority of the high-do
229 y attenuated upon adjustment for LV mass and
interim myocardial infarction (hazard ratio, 0.84; 95% c
230 gs and regimens are associated with improved
interim outcomes and acceptable safety profiles in adult
231 ol to trastuzumab emtansine after the second
interim overall survival analysis (median follow-up dura
232 ol to trastuzumab emtansine after the second
interim overall survival analysis crossed the prespecifi
233 ficant, the results of the first pre-planned
interim overall survival analysis indicated that everoli
234 Interim overall survival analysis showed a trend favouri
235 A preplanned
interim overall survival analysis was conducted.
236 At the preplanned
interim overall survival analysis, which was performed a
237 report the final PFS analysis and the first
interim overall survival analysis.
238 g was based on progression-free survival and
interim overall survival data from the phase 3 EMILIA st
239 At 6 months, the
interim overall survival rate was 93% with dabrafenib-tr
240 Interim performance of the resource is compromised by va
241 In the
interim period before transplantation, hypomethylating a
242 nt or increased tumor vascularization on the
interim PET (DeltaBF cutoff = -30%; P = 0.03), non-breas
243 One hundred
interim PET (i-PET) and 95 end-of-treatment PET (EoT-PET
244 Forty-three had
interim PET (iPET) performed after 2 cycles (iPET2), 95
245 Response-adapted therapy based on
interim PET imaging after two cycles of ABVD seems promi
246 Escalation of therapy based on
interim PET in pediatric HL needs further conclusive evi
247 the ABVD regimen after negative findings on
interim PET resulted in a lower incidence of pulmonary t
248 ional studies aimed at assessing the role of
interim PET scanning in HL, were retrospectively include
249 when needed, and no treatment adaptation on
interim PET scanning was allowed.
250 ority of patients (>/=90%) achieved negative
interim PET scans after 2 and 4 cycles of BV + AVD.
251 f the 1119 patients (83.7%) who underwent an
interim PET-CT scan according to protocol had negative f
252 rbazine) chemotherapy, and then underwent an
interim PET-CT scan.
253 Event-free survival based on
interim PET/CT (RIW) response was 93.3 +/- 4.1 versus 89
254 The specificity of
interim PET/CT based on RIW criteria (61.5%) and Deauvil
255 Interim PET/CT has better specificity, and use of Deauvi
256 Conclusion:
Interim PET/CT has better specificity, and use of Deauvi
257 Our results confirmed that an
interim PET/CT scan has limited prognostic value in pati
258 At this point,
interim PET/CT scanning is not ready for clinical use to
259 % versus 76% (P < .001) for patients who had
interim PET/CT scans after two cycles of R-CHOP-14 and 2
260 Central review of the
interim PET2 scan was performed in 331 evaluable patient
261 d response-adapted treatment guided by early
interim positron emission tomography (PET)-computed tomo
262 opsies from 31 patients and results of early
interim positron emission tomography/computed tomography
263 We tested
interim positron-emission tomography-computed tomography
264 The HealthNuts study previously reported
interim prevalence data showing the highest prevalence o
265 This approach would provide
interim protection to vulnerable, RSV-naive infants and
266 se uncertainties are then prioritised via an
interim ranking survey and a final workshop to achieve c
267 trajectory approach applied to the ECMWF-ERA-
interim reanalysis data.
268 Committee on Immunization Practices made an
interim recommendation not to use the live attenuated in
269 report, to provide health professionals with
interim recommendations about syndromic recognition and
270 hat even if complete recovery is reached, an
interim recovery debt will accumulate.
271 35 sampling plots worldwide, to quantify the
interim reduction of biodiversity and functions occurrin
272 Here we leverage an
interim release of UK Biobank (UKBB) data to evaluate th
273 s or special populations, duplicate reports,
interim reports superseded by a final report, studies of
274 Interim restaging with functional imaging by positron em
275 ntinue to follow people in this study, these
interim results are reassuring for the safety of kidney
276 ted elderly patients and moderately positive
interim results for lowering amyloid in pre-dementia Alz
277 Interim results from an ongoing prospective, multicenter
278 We present the 3-year
interim results of the 5-year prospective, randomized tr
279 INTERPRETATION: Our
interim results suggest that evolocumab is an effective
280 id-lowering or antihypertensive therapy, and
interim revascularization did not explain the overestima
281 We discontinued randomisation at
interim review when the futility boundary was crossed.
282 After an
interim review, the trial's placebo group was discontinu
283 A scheduled
interim safety analysis led to a reduction in the starti
284 e 172 patients with positive findings on the
interim scan, and 74.4% had negative findings on a third
285 redictors of PFS and OS than findings on the
interim scan.
286 ended for patients with negative findings on
interim scans.
287 pendent of the number of courses received or
interim staging.
288 ence suggests hemostatic resuscitation as an
interim standard of care for transfusion in critically i
289 MetS was defined by the Joint
Interim Statement criteria.
290 each participant were then incorporated into
interim statistical modelling to target the two doses mo
291 The prespecified
interim stopping boundary was crossed, and the study was
292 We review and compare onsite storage,
interim storage, and a geologic repository, as well as h
293 In this
interim subset analysis of the TAUSSIG study, which was
294 Interim TOP data confirm natalizumab's overall safety pr
295 Interim transplant-free survival over 12 years in this F
296 performed an emotion regulation task; in the
interim,
veterans with PTSD were treated with the SSRI,
297 -face meeting upon returning for care visit,
interim visit call, appointment reminder calls, missed v
298 n carried forward method for missing data at
interim visits.
299 By 2013, most outbreaks in the
interim were promptly controlled.
300 s soon as practical, with limited use in the
interim where no viable IRS alternatives exist.